More on IKT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+7.7% Growth)
- Ratings (7.5 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Inhibikase Therapeutics (NQ:IKT)
Delayed: 1.59 -0.04 (2.45%)
Prev. Close $1.63  
Open$1.60 
52 Wk High$ 
52 Wk Low$ 
Day High$1.65 
Day Low$1.54 
P/E N/A  
EPS$ 
Volume408,796 


Oct 21, 2026 04:10 PM Form 4 Inhibikase Therapeutics, For: Oct 19 Filed by: Wasserman Scott M.
Oct 21, 2026 04:05 PM Form 3 Inhibikase Therapeutics, For: Oct 19 Filed by: Wasserman Scott M.
Oct 20, 2026 04:58 PM Form 8-K Inhibikase Therapeutics, For: Oct 19
Oct 20, 2026 04:01 PM Inhibikase adds cardiologist Scott Wasserman to its board
Oct 20, 2026 04:01 PM Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Oct 13, 2026 02:59 AM Chardan Starts Inhibikase Therapeutics Inc (IKT) at Neutral
Oct 2, 2026 04:01 PM Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 26, 2026 04:07 PM Form 8-K Inhibikase Therapeutics, For: Aug 21
Aug 14, 2026 05:23 PM Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Aug 14, 2026 04:48 PM Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC
View All Articles

Entities mentioned with IKT

View All Entities